StoryFunding
Generate Biomedicines begins trading on Nasdaq after a $400M IPO
Generate Biomedicines priced its IPO at $16.00 per share for 25 million shares, raising $400 million in gross proceeds. The company began trading on the Nasdaq Global Select Market on 27 February 2026 under ticker GENB. Goldman Sachs and Morgan Stanley led the offering, with Piper Sandler, Guggenheim Securities and Cantor as book-running managers.
- $16.00 per share; 25 million shares offered ($400M gross proceeds)
- Underwriters' 30-day option for 3.75 million additional shares
- Trading began February 27, 2026 on Nasdaq Global Select Market under ticker GENB
- Lead underwriters: Goldman Sachs and Morgan Stanley; additional managers: Piper Sandler, Guggenheim, Cantor